Large 5 country cohort study - No increased risk of hematologic malignancies (lymphoid or myeloid) in PsA pts treated with TNFi. In PsA overall compared to general population - moderately increased underlying risk of hematologic malignancies. @RheumNow #EULAR2022 ABST#OP0257 https://t.co/P846RupitR

#OP0783 #EULAR2022 A study in Spain (N=72) of #Sjogren pts showed Pathologic US of salivary glands were associated with Ro52+, raised IgG, early menopause & lack Mediterranean diet. Smoking was protective but wide Confidence Interval. I wont promote smoking though @RheumNow https://t.co/kn4X4oFGzK

Female PsA patients on TNFi have reduced treatment effectiveness, LDA (vs males). #EULAR2022 POS0077 @RheumNow https://t.co/EwDwxUarNb https://t.co/W5xgQlrnlF

• POS0077 SEX DIFFERENCES IN EFFECTIVENESS OF FIRST-LINE TUMOR NECROSIS FACTOR IN…

Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow

#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh

#EULAR2022 Telemedicine: PROs 💻Triage, reduce wait time, direct other specialty referral 💻High agreement w F2F evaluation (79-97%) 💻Saves resources, react quickly to minor flare 💻Better adherence @RheumNow

BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6

#EULAR2022 R Landewe: Anti-Telemedicine 🩺Rheumatology about long-term relationship & communication 🩺"Telemedicine impoverishes visit" by only exchanging information @Rheumnow

#POS0752 #EULAR2022 Is there difference btw childhood- vs adult-onset #lupus?A cohort study of claims database >10,000 pts showed: Children had higher activity & more likely to receive immunosuppressant Some activities persisted Useful to bear in transition clinic @RheumNow https://t.co/KVHZUgAOlV

Inflammation (ESR >20 and cardiovascular risk scores) in AxSpA pts associated with incident hypertension. csDMARD may be associated with HTN NSAID and biologics not associated with incident HTN @RheumNow #EULAR2022 ABST#POS0154 https://t.co/5pYjXrpCec

#PEARLS by EULAR President Prof Iagnocco: 1. Enthesitis can be present in 25% of #SLE patients 2. Erosions can be common and independent of ACPA/RF status 3. Active myositis is indistinguishable from IIM 4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve

#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH

Staggering facts by Prof Vital on #SLE and SkM Sx’s: - 50% of first Sx’s is SkM - SkM Sx are in top 3 concerns for pts - 34% pts w/SkM Sx stopped working median 4 yrs - SkM damage clusters with CVD damage #EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ

📲The great debate on Telemedicine 💻 R. Landewe warns us against "check box medicine" and its consequences on AxSpA overdiagnosis. @RheumNow #EULAR2022 https://t.co/Xwg0aAdHwE

“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs